KR840006437A - 항생제 경구 투여용 제형의 제조방법 - Google Patents

항생제 경구 투여용 제형의 제조방법 Download PDF

Info

Publication number
KR840006437A
KR840006437A KR1019830004866A KR830004866A KR840006437A KR 840006437 A KR840006437 A KR 840006437A KR 1019830004866 A KR1019830004866 A KR 1019830004866A KR 830004866 A KR830004866 A KR 830004866A KR 840006437 A KR840006437 A KR 840006437A
Authority
KR
South Korea
Prior art keywords
fatty acids
mixture
product
mono
enhancer
Prior art date
Application number
KR1019830004866A
Other languages
English (en)
Inventor
벨(외 4) 샤란지트
Original Assignee
진-쟉케스 오가이, 게젤샤프트 마인라드 슈미트
에프. 호프만-라롯슈 앤드 캄파니 아크티엔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진-쟉케스 오가이, 게젤샤프트 마인라드 슈미트, 에프. 호프만-라롯슈 앤드 캄파니 아크티엔 filed Critical 진-쟉케스 오가이, 게젤샤프트 마인라드 슈미트
Publication of KR840006437A publication Critical patent/KR840006437A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Abstract

내용 없음

Description

항생제 경구 투여용 제형의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 항생제를, 지방족 C2-C18지방산, C2-C12지방산으 모노글리세라이드, 디글리세라이드 및 트리글리세라이드, C2-C12지방상과프로필렌글리콜, 폴리에틸렌글리콜 및 탄수화물의 부분 및 전체 에스테르, 그들의 약학적으로 허용된 에스테르 및 에테르 및 언급된 증진제들의 혼합물 등으로부터 선택된 증진제의 흡수 증진량과 혼합하고, 경우에 따라서는 혼합 생성물을 약학적으로 허용되는 담체와 혼합시킴을 특징으로 하여 실제적으로 경구 비활성인 β-락탐 항생제로부터 장내투여시 활성인 생성물을 제조하는 방법.
  2. 제1항에 있어서, 혼합생성물을 장용피 형태로 변형시킴으로써 경구 활성인 생성물로 전환시키는 방법.
  3. 제1항에 있어서, β-락탐 항생제와 지방산 또는 글리세라이드 또는 그들의 혼합물을 용액 또는 현탁제로 혼합시키는 방법
  4. 제1항 또는 2항에 있어서, β-락탐 항생제와 지방산 또는 글리세라이드 또는 그들의 혼합물을 고체혼합물로 혼합시키는 방법
  5. 제1항 내지 4항중 어느 한 항에 있어서, 증진제로서 글리세라이드, 또는 모노글리세라이드, 성분이 다량 함유된, 지방산의 모노- 및 디글리세라이드의 혼합물을 사용하는 방법.
  6. 제1항 내지 5항중 어느 한 항에 있어서, 생성물이, β-락탐 항생제가 약 25mg 내지 약 2000mg의 양으로 함유된 투여형태로 제조되는 방법.
  7. 제6항에 있어서, β-락탐 항생제가 약 50 내지 약 500mg의 양으로 사용된 방법.
  8. 제1항 내지 7항중 어느 한 항에 있어서, 증진제로서 C8-C12지방산의 글리세라이드 혼합물이 사용된 방법.
  9. 제1항 내지 8항중 어느 한 항에 있어서, 증진제로서 글리세라이드 혼합물이 조성물 중량의 약 33% 내지 약 98%로 사용된 방법.
  10. 제9항에 있어서, 글리세라이드 혼합물이 조성물 중량의 약 89%로 사용된 방법.
  11. 제1항 내지 10항중 어느 한 항에 있어서, 생성물이 장용피깝셀, 마이크로깝셀 또는 비드렛(beadlet)과 같은 투여형태로 제조되는 방법.
  12. 제1항, 2항 및 4항 내지 10항중 어느 한 항에 있어서, 생성물이 정제와 같은 투여 형태로 제조되는 방법.
  13. 제1항 내지 12항중 어느 한 항에 있어서, 증진제로서, 모노글리세라이드가 모노/디글리세라이드 혼합물의 약 70% 또는 약 90%로 존재하는 C8/C10포화 지방산의 모노- 및 디글리세라이드의 혼합물을 사용하는 방법.
  14. 제1항 내지 13항 중 어느 한 항에 있어서, 세프트리악손이 β-락탐 항생제로 사용된 방법.
  15. 제1항 내지 13항중 어느 한 항에 있어서, β-락탐 항생제가 세폭시틴, 티에나마이신, 아즈트레오남, 목살락탐, 세팔로친, 세파만돌, 세포탁심, 세포페라존, 메즈로실린, 피페라실린,세파졸린, 암디노실린 및 페니실린 G로부터 선택된 방법.
  16. 제1항 내지 14항중 어느 한 항에 있어서, 세프트리악손이 β-락탐 항생제로 사용되고, 증진제로서는 모노글리세라이드가 모노/디글리세라이드 혼합물의 약 70% 또는 약 90%로 존재하는 C8/C10포화지방산의 모노- 및 디글리세라이드 혼합물이 사용된 방법.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830004866A 1982-10-15 1983-10-14 항생제 경구 투여용 제형의 제조방법 KR840006437A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US434452 1982-10-15
US06/434,452 US4525339A (en) 1982-10-15 1982-10-15 Enteric coated oral dosage form

Publications (1)

Publication Number Publication Date
KR840006437A true KR840006437A (ko) 1984-11-30

Family

ID=23724297

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830004866A KR840006437A (ko) 1982-10-15 1983-10-14 항생제 경구 투여용 제형의 제조방법

Country Status (14)

Country Link
US (1) US4525339A (ko)
EP (1) EP0108295A1 (ko)
JP (1) JPS59104312A (ko)
KR (1) KR840006437A (ko)
AU (1) AU2019283A (ko)
DK (1) DK473183A (ko)
FI (1) FI833728A (ko)
GR (1) GR82301B (ko)
IL (1) IL69960A0 (ko)
MC (1) MC1550A1 (ko)
NO (1) NO833757L (ko)
PT (1) PT77503A (ko)
ZA (1) ZA837307B (ko)
ZW (1) ZW22183A1 (ko)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60146825A (ja) * 1984-01-10 1985-08-02 Asahi Chem Ind Co Ltd 経口医薬製剤
CA1256799A (en) * 1984-02-22 1989-07-04 Walter Fuller Suppositories
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
US5260271A (en) * 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA906186B (en) * 1989-09-11 1991-06-26 Hoffmann La Roche Pharmaceutical preparations
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
AT393955B (de) * 1990-03-30 1992-01-10 Martin Dr Leixnering Einrichtung zur nachbehandlung frischer beugesehnenverletzungen
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
JP3350054B2 (ja) * 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
UA82824C2 (uk) 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001266347A1 (en) * 2000-07-11 2002-01-21 Shionogi And Co., Ltd. Enteric preparations containing physiologically active peptides
WO2002092069A1 (en) * 2001-05-11 2002-11-21 Elan Corporation, Plc Permeation enhancers
EP1390024A4 (en) * 2001-05-11 2010-02-17 Merrion Res Iii Ltd ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
CA2606386C (en) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
PL2197429T3 (pl) 2007-09-03 2016-09-30 Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków
EP2214635A1 (en) * 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20140228312A1 (en) * 2011-10-03 2014-08-14 Agency For Science, Technology And Research Antibiotic composition and its uses
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
WO2019036770A1 (en) * 2017-08-24 2019-02-28 University Of South Australia ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567598A (ko) *
US2476351A (en) * 1945-06-07 1949-07-19 Parke Davis & Co Injectable penicillin compositions
US2487336A (en) * 1946-02-25 1949-11-08 William E Hinds Penicillin product
US2443778A (en) * 1947-04-21 1948-06-22 Monroe J Romansky Preparations for penicillin therapy
US2566200A (en) * 1947-06-07 1951-08-28 Commercial Solvents Corp Oral therapeutic tablets
US2507193A (en) * 1949-05-17 1950-05-09 Bristol Lab Inc Penicillin product
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2902407A (en) * 1955-06-14 1959-09-01 Commercial Solvents Corp Wax-coated penicillin product
US2864744A (en) * 1955-09-02 1958-12-16 American Home Prod Penicillin in solid dosage unit form
US3016330A (en) * 1955-11-10 1962-01-09 Novo Terapeutisk Labor As Therapeutical antibiotic composition
US2951014A (en) * 1957-01-03 1960-08-30 Upjohn Co Process for a stable oil suspension
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
NL297631A (ko) * 1963-06-03
US3849569A (en) * 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
GB1226555A (ko) * 1967-08-08 1971-03-31
US3626056A (en) * 1967-11-02 1971-12-07 Bristol Myers Co Oral antibiotic product
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3538215A (en) * 1969-06-13 1970-11-03 Allied Chem Stabilized antibiotic in liquid ruminant feed supplement
GB1312918A (en) * 1969-07-08 1973-04-11 Beecham Group Ltd Veterinary treatment
US3696189A (en) * 1970-05-18 1972-10-03 Frank M Snyder Stabilized antibiotic and method
US3655864A (en) * 1970-09-21 1972-04-11 Smith Kline French Lab Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption
JPS4971127A (ko) * 1972-11-18 1974-07-10
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4145429A (en) * 1974-09-21 1979-03-20 Beecham Group Limited Oral veterinary preparations
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
GB1547164A (en) * 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
JPS5283924A (en) * 1976-01-01 1977-07-13 Sumitomo Chem Co Ltd Preparation of pharmaceuticals for rectal infusion containing penicill ins and cephalosporins
JPS6055486B2 (ja) * 1976-02-28 1985-12-05 富山化学工業株式会社 β−ラクタム環を有する化合物の直腸投与用組成物
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
DE2654844A1 (de) * 1976-12-03 1978-06-08 Kali Chemie Pharma Gmbh Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
IL58462A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a penicillin
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
JPS56104812A (en) * 1980-01-23 1981-08-20 Sankyo Co Ltd Production of cephalosporin compound preparation for rectal infusion
JPS5799519A (en) * 1980-12-12 1982-06-21 Toyo Jozo Co Ltd Stable suppository and its preparation

Also Published As

Publication number Publication date
EP0108295A1 (de) 1984-05-16
NO833757L (no) 1984-04-16
ZW22183A1 (en) 1985-04-17
ZA837307B (en) 1984-06-27
US4525339A (en) 1985-06-25
AU2019283A (en) 1984-04-19
FI833728A0 (fi) 1983-10-13
PT77503A (en) 1983-11-01
MC1550A1 (fr) 1984-08-31
FI833728A (fi) 1984-04-16
GR82301B (ko) 1984-12-13
DK473183D0 (da) 1983-10-13
JPS59104312A (ja) 1984-06-16
DK473183A (da) 1984-04-16
IL69960A0 (en) 1984-01-31

Similar Documents

Publication Publication Date Title
KR840006437A (ko) 항생제 경구 투여용 제형의 제조방법
KR850000975A (ko) 발프로익산과 그 염의 혼합물을 토대로 한 조성물
DE3171928D1 (en) Pharmaceutical formulation and its preparation
KR910014120A (ko) 피모벤단의 경구용 약제학적 제제
JO2324B1 (en) Pharmaceutical compounds for topical oral use
JPS5350141A (en) Stabilization of prostaglandin and prostaglandin analogues
JPS5350316A (en) Drug composition for oral administration
JPS52806A (en) Preparation of ester
DE3462490D1 (en) 5-aminosalicylic acid-0-sulfates of physiologically acceptable bases, process for their production and medicines containing them
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
ES8306593A1 (es) Procedimiento de preparar agentes farmaceuticos administra- bles por via topica
JPS5668619A (en) Nifedipine-containing solid composition
JPS5731614A (en) Lipid improver
JPS5326316A (en) Drug containing active vitamin d3 derivatives and its preparation
JPS52130905A (en) Medicinal composition
RU2000108267A (ru) Фармацевтические композиции на основе нестероидных противовоспалительных средств
JPS5564755A (en) Shortening for "baumkuchen" (germany cake)
JPS56145223A (en) Drug composition
KR950703333A (ko) 비이온계 계면활성제 함유 약학 조성물(Pharmaceutical Compositions Containing Nonionic Surfactants)
JPS5484034A (en) Anti-tumor agent
JPS5665819A (en) Composition for mefenamic acid pharmaceutical
JPS5251362A (en) Preparation of optically active pyrrolidine derivatives
JPS545948A (en) Cyclopropanecarboxylic acid esters, process for their prparation, and isecticide having low toxicity to fishees, containing the same as active constituents
JPS5640607A (en) Drug composition
GB890638A (en) Compositions for combating retinitis pigmentosa

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid